Disease overview: Epstein Barr virus-positive (EBV1) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV1 DLBCL, NOS, is an aggressive B-cell lymphoma associated with chronic EBV infection, and a poor prognosis with standard chemotherapeutic approaches.
pattern III is associated with a marked immunodeficiency state. Other Clinically, patients tend to be diagnosed at an older age; hence the former reference to the term "elderly." In addition to common nodal involvement and high International Prognostic Index (IPI) scores, patients tend to have higher rates of extranodal involvement with the gastrointestinal tract, skin and bone marrow being the most commonly affected sites. Also, there is higher proportion of patients with elevated LDH levels, and more advanced clinical stage, as well as worse performance status than patients with EBV-negative DLBCL.
Expectedly, the definition of EBV1 DLBCL, NOS, continues evolving. Recent evidence shows that EBV1 DLBCL, NOS, can be seen in young, immunocompetent individuals. [9] [10] [11] [12] These studies have shown similar virological and pathological findings between younger and older patients with EBV1 DLBCL, NOS. It is important to note that there is no clear cutoff for a positive expression of EBER as previously published studies have used rates of positivity ranging from 10% to 50%. 13 This is further complicated by the recent report that small bystander EBV1 lymphocytes in the microenvironment, but not in the large neoplastic cells, appear to convey a distinct poor prognosis. 14 
| D I A GN OSI S
The WHO recognizes that there is a pathologic spectrum of large cells, either a predominance of large cells with a diffuse pattern as in any DLBCL, 15 or a more common appearance is that of scattered large cells amidst a reactive background with numerous small lymphocytes or histiocytes, reminscent to T-cell/histocyte-rich large B cell lymphoma (THRLBL) and previously denominated as the polymorphous subtype. 13 The large cells may appear as large centroblasts, immunoblasts, some- Figure 1 ). However, no prognostic significance has been associated with the morphologic subgroups. 16 The lymphoma cells express Comparative genomic hybridization of eight PEL cases showed gain of chromosomes 12 and X in three and two cases, respectively, and amplification within the 1q region in two cases. 35 BCL-2, BCL-6, and MYC genes were not rearranged, and mutations in MYC, HRAS, KRAS, NRAS, and TP53 genes were not found. 36 Clonal rearrangement of the immunoglobulin gene is seen in most cases and can be used for determining lineage. Gene expression profiling showed that PEL is in the differentia- 38 It has a spectrum of lesions from scattered plasmablasts in the mantle zones of reactive germinal centers to DLBCL, however these tumors do not exhibit EBV infection, and EBER is negative.
EBV1 mucocutaneous ulcer is an ulcerative process associated with EBV infection presenting usually in the head and neck region as well as in gastrointestinal mucosa. 39 Further details useful in the differential diagnosis of these entities are shown in Table 1 . 40 Of note, only a minority of patients, however, received rituximab as part of their therapy in these studies.
There has been a number of reports on the use of chemoimmunotherapy in patients with EBV1 DLBCL, NOS, with disparate results. In a multicenter consortium study on DLBCL patients treated uniformly with R-CHOP, the response and survival rates of 28 patients with EBV1 DLBCL, NOS, was compared with 695 EBV-negative patients, and showed no statistical differences. 18 Pathologically, there was a higher rate of CD30 expression in EBV1 patients. Similar results were found in a Korean study that evaluated 18 patients with EBV1 DLBCL, NOS, who had similar OS rates to 204 EBV-negative patients with 3-year OS rates of 57% and 60%, respectively. 41 Conversely, a Japanese study showed a median OS of 9 months in 8 patients with EBV1
DLBCL, NOS, treated with R-CHOP while the median OS for EBVnegative patients was not reached. 42 A Spanish study on 47 patients with EBV1 DLBCL mostly treated with R-CHOP-like regimens showed 2-year OS rate of 40%, which appeared lower than patients with EBVnegative DLBCL. 16 A Chinese study also found worse outcomes in patients with EBV1 DLBCL with median OS of 18 months versus median OS that was not reached in EBV-negative patients, although it was not specified the proportion of patients who received chemotherapy and chemoimmunotherapy. 10 A recent Peruvian study showed encouraging results with the use of R-CHOP in 17 patients with EBV1 DLBCL, NOS. 43 The OR and CR rate were 71% and 59%, respectively, and a 5-year OS rate of 54%. These findings were similar to the response and survival rates in EBV-negative DLBCL patients. However, in other more recent Asian studies, the use of R-CHOP was associated with poorer survival outcomes in patients with EBV1 DLBCL, NOS, when compared with EBV-negative DLBCL patients. 44, 45 An early study reported EBV1 status was less frequent in DLBCL patients younger than 50 than in older than 50 (7 vs 9%, respectively) and had no impact on PFS and OS when treated with R-CHOP. 46 In summary, patients with EBV1 DLBCL have a worse prognosis than EBV-negative patients when treated with chemotherapy. The outcomes appear somewhat better, although less favorable, when EBV1
DLBCL patients are treated with chemoimmunotherapy.
| Other prognostic factors
The IPI score is one of the most commonly used risk stratification tools in DLBCL. In an early report, the IPI score appeared to be of limited prognostic value in patients with EBV1 DLBCL. 3 A prognostic index that consisted on age older than 70 years and presence B symptoms was designed. Patients with zero, one or two factors showed median OS times of 56, 25 and 9 months, respectively. In a smaller study, Beltran and colleagues identified higher IPI and higher Oyama scores to be associated with worse outcome in patients with EBV1 DLBCL. 4 In this study, a notable adverse prognostic factor was lymphopenia defined as an absolute lymphocyte count of <1.0 3 10 9 /L.
CD30 expression is not only increased in, but also associated with a worse OS in patients with EBV1 DLBCL. 18 In this study, EBER1/ CD301 DLBCL patients had worse outcome than EBER1/CD30-or EBER-/CD301 DLBCL patients. Survivin affects cellular apoptosis through indirect mechanisms that lead to inhibition of caspase 9. 47 In DLBCL treated with R-CHOP, high expression of survivin in tumor cells was associated with poor outcomes, especially in the ABC subtype. 48 Serum levels of survivin were high in 12% of DLBCL patients. Higher levels were seen in EBV1 than in EBV-negative DLBCL cases (19 vs.
5%, respectively). High serum survivin levels and were associated with poor outcomes. 44 
| M A NA GE M EN T OF E BV 1 D LB CL , NOS
The addition of the anti-CD20 chimeric monoclonal antibody, rituximab, Table 2 . Thus, there is not a standard approach for EBV1 DLBCL and treatment options usually are in concordance with current strategies for de novo DLBCL.
| F U TU RE D I RE CTI ON S
Novel therapies that will address viral replication, targeting specific pathways in EBV1 DLBCL and improving/modulating the immune response against EBV have been investigated and seem promising in the treatment of this condition.
Typical antiviral therapies are not effective in eradicating EBV from chronically and transformed B-cells. In order for ganciclovir and acyclovir to show antiviral activity, they require proteins of lytic phase to be active, however EBV maintains a latent-phase in B-cell infected cells. 52 Thus, induction of EBV into a lytic phase could lead to an effective exposure to antiviral therapy. 53 Inducers of lytic phase include methylase transferase inhibitors, histone deacetylase inhibitors (HDACs), and proteasome inhibitors among others. 13, 53 Arginine butyrate, which has HDACs properties, and gancyclovir were administered to 15 patients with refractory EBV1 B-cell lymphomas. There were 10 responses with 4 complete responses. 54 Other HDACs, such as panobinostat and belinostat have shown a synergistic effect by sensitizing EBV1 lymphoma cell lines to ganciclovir, however clinical efficacy is yet to be proven.
55
EBV1 DLBCL has an activated B-cell (ABC) DLBCL profile and is characterized by increased activation of the NF-kB pathway. The proteasome inhibitor bortezomib has induced apoptosis in EBV transformed B-cells and mouse models. 56 However, the addition on bortezomib to chemoimmunotherapy have been of modest benefit in DLBCL. 57, 58 Lenalidomide can also target ABC DLBCL by down regulating IRF4 and NF-kB. 59 Early clinical data showed preferential activity in ABC DLBCL. 60 Studies adding lenalidomide to R-CHOP in newly diagnosed DLBCL have shown encouraging results, either concurrently with R-CHOP or as maintenance following R-CHOP. 61, 62 Ibrutinib is an inhibitor of the Bruton Tyrosine Kinase (BTK), an important component of the B-cell receptor (BCR) pathway. In a study of 80 patients with refractory/relapsed DLBCL, ibrutinib induced an OR rate in ABC DLBCL and GCB DLBCL of 37% and 5%, respectively. 63 A randomized study of R-CHOP with or without ibrutinib in ABC DLBCL (NCT01855750) and a phase II study evaluating ibrutinib and R-CHOP in EBV1 DLBCL (NCT02670616) are ongoing. The PI3K kinase pathway seems to be critical for upstream signaling of NF-kB in ABC DLBCL cell lines, thus inhibition of the PI3K pathway appears to be another approach for EBV1 DLBCL with ABC signature. 64, 65 EBV blocks the expression of the highly immunogenic proteins during latency and expresses lytic proteins that impairs antigen processing by infected cells and by producing viral cytokines that impairs the immune system. 66 Efficacy of adoptive T-cell therapy using specific EBV cytotoxic T-cells (CTLs) was evaluated in patients with EBVrelated PTLD in 1995. 67, 68 The most common method for development of specific EBV CTLs is to establish LCLs by in vitro EBV infection. 69 The infusion of EBV CTLs was effective as treatment, in cases of PTLD, and as a prophylaxis, in patients undergoing transplantation. 70, 71 Although effective, the time to manufacture CTLs (up to 6-12 weeks) may be too long for a patient with an aggressive lymphoma. To generate CTLs in a rapid manner, donor-derived EBNA1-specific T-cells were developed by a faster method using cytokine secreting system with selection of interferon-gamma secreting EBNA1-specific cells. The process to generate these EBV-CTLs takes approximately 3 days. In a study of 10 patients with EBV1 refractory PTLD after allogeneic HSCT, the administration of EBNA1-specific EBV-CTLs was able to restore T-cell immunity against EBV and induced a response rate of 70%. 72 In immunocompetent patients, generation of CTLs using this methodology did not yield the same efficacy with a response rate of 30% in patients with EBV1 Hodgkin lymphoma. 73 In an effort to improve immunogenicity and expand the EBV antigen profile potentially targeted by CTLs, dendritic cells transduced by adenovirus and EBV transformed LCL as antigen-presenting cells were used to activate and expand LMP-1/2 specific T-cells. In this trial of 50 patients with EBV1 lymphomas, the response rate was 64%. 74 A potential biomarker with therapeutic implications is the expression of program death ligand 1 (PD-L1) in EBV1 DLBCL. Upregulation of PD-L1 is a mechanism of immune evasion on several cancers by inactivating anti-tumor T-cells responses. 75 Increased serum soluble PD-L1 was associated with poor prognosis in DLBCL patients treated with R-CHOP. 76 PD-L1 expression was positive in 100% of patients with EBV1 DLBCL as opposed to DBLCL, NOS (11%). 77 Expression PD- L1 in tumor cells and microenvironment (mPD-L1) was studied in a larger study (n 5 1557); of those 114 (9%) had positive EBER expression. The expression of PD-L1 and mPD-L1 was significantly associated with EBV1 status. Additionally, PD-L1 and mPD-L1 expression was noted in 16 and 41% of patients with EBV1 DLBCL. 78, 79 A study restricted to younger EBV1 DLBCL patients showed increased PD-L1 in tumor cells as well as nonmalignant histiocytes. 11 Preclinical data showed that PD-1 blockade was associated with restoration of proliferation and activation of T-cells in PD-L11 EBV1 DLBCL in greater degree than PD-L11 EBVnegative DLBCL. 80 Thus, targeting the PD-L1/PD-1 pathway represents a potential therapeutic approach for EBV1 DLBCL. There are ongoing studies using durvalumab (NCT03212807), a PD-L1 inhibitor, and nivolumab (NCT02973113), a PD-1 inhibitor, in combination with EBV CTLs in refractory EBV1 lymphomas.
Chimeric antigen receptor (CAR) T-cells directed against tumorassociated markers, such as CD19, are undergoing clinical development in leukemia and lymphoma. 81, 82 There is preclinical evidence of efficacy of LMP1-directed CAR T-cell in nasopharyngeal carcinoma, a malignancy associated with EBV infection. 83 Thus, immunotherapy seems to offer an interesting and effective alternative for patients with EBVrelated lymphomas, in particular EBV-positive DLBCL of the elderly given its success and tolerability. 
